The legacy of Viagra and its effect on the drug landscape presents a thorny question for shareholders . Initially a massive drug, generics have significantly chipped away at its market share , creating difficulties for companies involved to the original patent holder and related formulas. While certain firms might benefit from niche Viagra-related